How I treat ovarian cancer in older women

Lichtman, Stuart M.

doi:10.1016/j.jgo.2014.06.001

Cited by 9 publications

(5 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Patients older than 70 years comprise a significant proportion of patients with a new diagnosis of ovarian cancer each year; by some estimates almost half of new diagnoses. 3,4 Patient age has been recognized as an important predictor of long-term outcomes in ovarian cancer, with older patients facing less robust survival than younger patients. 4,5 The reasons for this difference are unclear and may reflect differences in tumor biology, less aggressive treatment, and increased medical frailty or complexity of comorbidities.…”

mentioning

confidence: 99%

“…3,4 Patient age has been recognized as an important predictor of long-term outcomes in ovarian cancer, with older patients facing less robust survival than younger patients. 4,5 The reasons for this difference are unclear and may reflect differences in tumor biology, less aggressive treatment, and increased medical frailty or complexity of comorbidities. 3,4,6,7 To determine the optimal therapeutic approach for elderly patients with ovarian cancer, one must consider the risks associated with each phase of treatment and how age may impact a patient's ability to withstand the adverse effects and complications of each intervention.…”

mentioning

confidence: 99%

“…4,5 The reasons for this difference are unclear and may reflect differences in tumor biology, less aggressive treatment, and increased medical frailty or complexity of comorbidities. 3,4,6,7 To determine the optimal therapeutic approach for elderly patients with ovarian cancer, one must consider the risks associated with each phase of treatment and how age may impact a patient's ability to withstand the adverse effects and complications of each intervention. Currently, the most effective treatment of ovarian cancer combines surgical resection of all visible disease in the pelvis and abdomen with multidrug chemotherapy.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Impact of Age on 30-Day Mortality and Morbidity in Patients Undergoing Surgery for Ovarian Cancer

Mahdi

Wiechert

Lockhart

et al. 2015

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Impact of Age on 30-Day Mortality and Morbidity in Patients Undergoing Surgery for Ovarian Cancer

Mahdi

Wiechert

Lockhart

et al. 2015

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…In a retrospective study of 85 patients over the age of 80 undergoing cytoreductive surgery, 13% died prior to discharge and 20% died within 60 days of surgery 26 . In a pragmatic paper on the treatment of ovarian cancer in older women, Dr Lichtman proposes how to approach decision-making 27 . The surgeon should consider two factors: firstly, if the disease is anatomically amenable to optimal resection, and, secondly, whether the patient is able to tolerate the surgery with acceptable risk.…”

Section: Gynecological Cancermentioning

confidence: 99%

Recent advances in cancer surgery in older patients

Rostoft

Audisio

2017

F1000Res

View full text Add to dashboard Cite

Age is the most important risk factor for the occurrence of cancer, and a declining mortality from heart disease and other non-cancer causes leaves an older population that is at high risk of developing cancer. Choosing the optimal treatment for older cancer patients may be a challenge. Firstly, older age and associated factors such as comorbidities, functional limitations, and cognitive impairment are risk factors for adverse effects of cancer treatment. Secondly, older patients are often excluded from clinical trials, and current clinical guidelines rarely address how to manage cancer in patients who have comorbidities or functional limitations. The importance of incorporating frailty assessment into the preoperative evaluation of older surgical patients has received increasing attention over the last 10 years. Furthermore, studies that include endpoints such as functional status, cognitive status, and quality of life beyond the standard endpoints, i.e. postoperative morbidity and mortality, are starting to emerge. This review looks at recent evidence regarding geriatric assessment and frailty in older surgical cancer patients and provides a summary of newer studies in colorectal, liver, pancreatic, and gynecological cancer and renal and central nervous system tumors.

show abstract

“… 3 As a result, many OC patients are either misdiagnosed or diagnosed at later stages with poor prognosis. 4 Thus, it is critical to understand the molecular mechanisms involved in OC progress and to identify early and accurate screening markers of OC is especially important for OC management.…”

Section: Introductionmentioning

confidence: 99%

Circulating VEGF as a biomarker for diagnosis of ovarian cancer: a systematic review and a meta-analysis

Liang¹,

He²,

Zhong³

et al. 2015

OTT

View full text Add to dashboard Cite

VEGF is a frequently studied angiogenic factor in ovarian cancer (OC), and is considered to have an important role in the progression of OC. However, its diagnostic value has not been widely accepted because the conclusions are inconsistent and even conflicting. Therefore, we performed a meta-analysis to evaluate the diagnostic value of VEGF in OC. A systematic literature search was conducted using the PubMed, Cochrane Library, EMBASE, Chinese National Knowledge Infrastructure, and WANFANG databases for relevant published articles (the last search update was November 18, 2014). The diagnosis sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and the summary receiver operating characteristic curves were pooled by Meta DiSc 1.4 software. A total of ten studies with 1,131 subjects were finally included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and summary receiver operating characteristic curves were 0.67 (0.63–0.73), 0.78 (0.75–0.81), 3.08 (6.36–12.22), 0.39 (0.29–0.51), 9.10 (5.43–45.25), and 0.8175, respectively. Furthermore, to explore the sources of heterogeneity, we conducted subgroup analyses based on ethnicity and sample size. The diagnostic accuracy of VEGF was higher in an Asian population than in a Caucasian population. A similar finding was found in subgroups with the smaller sample size (<100 subjects). In conclusion, the present meta-analysis suggests that VEGF has moderate diagnostic accuracy for OC. Considering our limitations and the heterogeneity among our selected studies, larger, well-designed prospective and multicenter validation studies are needed to evaluate the diagnostic value of serum VEGF for OC.

show abstract

How I treat ovarian cancer in older women

Cited by 9 publications

References 56 publications

Impact of Age on 30-Day Mortality and Morbidity in Patients Undergoing Surgery for Ovarian Cancer

Impact of Age on 30-Day Mortality and Morbidity in Patients Undergoing Surgery for Ovarian Cancer

Recent advances in cancer surgery in older patients

Circulating VEGF as a biomarker for diagnosis of ovarian cancer: a systematic review and a meta-analysis

Contact Info

Product

Resources

About